
Bio Medica Laboratories IPO
- Issue price
- ₹139
- Listing price
- ₹111.2
- -20.00%
- Current price
- ₹150
- +7.91%
- Subscribed
- 2.31x
- Issue size
- ₹52 Cr
- Listed on
- 29 May 2026
IPO timeline
- Opens21 MayThu
- Closes25 MayMon
- Allotment26 MayTue
- Refunds27 MayWed
- Demat credit27 MayWed
- Listing29 MayFri
Issue details
- Price band
- ₹132 – ₹139 per share
- Issue size
- ₹52 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹10 per share
- Lot size
- 1,000 shares
- Minimum investment
- ₹1,39,000
- Listing on
- NSE SME
- Exchange code
- BMLL-SM · BMLL
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹1,39,000 |
| Retail (Max) | 1 | 1,000 | ₹1,39,000 |
| HNI (Min) | 2 | 2,000 | ₹2,78,000 |
Reservation
- QIB
- 36,000 shares (1.00% of the Offer)
- NII
- 17,55,000 shares (48.98% of the Offer)
- Retail
- 17,92,000 shares (50.01% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on Skyline Financial Services- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 26 May 2026
- Refunds initiated
- 27 May 2026
- Shares credited to demat
- 27 May 2026
- Listing
- 29 May 2026
Grey market premium (GMP)
- Current GMP
- ₹2
- +1.00%
- Estimated listing price
- ₹141
- Issue price ₹139
- Highest
- ₹4
- 22 May
- Lowest
- ₹0
- 18 May
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 27 May 2026 | ₹2 | +1.00% | ₹141 |
| 26 May 2026 | ₹2 | +1.00% | ₹141 |
| 25 May 2026 | ₹0 | — | ₹139 |
| 23 May 2026 | ₹2 | +1.00% | ₹141 |
| 22 May 2026 | ₹4 | +3.00% | ₹143 |
| 21 May 2026 | ₹0 | — | ₹139 |
| 20 May 2026 | ₹0 | — | ₹139 |
| 19 May 2026 | ₹0 | — | ₹139 |
| 18 May 2026 | ₹0 | — | ₹139 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB15.94x
- NII (HNI)1.41x
- Retail2.92x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 36,000 | 5,74,000 | 15.94x |
| Non-Institutional Investors (NII) | 17,55,000 | 24,75,000 | 1.41x |
| Retail Individual Investors (RII) | 17,92,000 | 52,26,000 | 2.92x |
| Total | 35,83,000 | 82,75,000 | 2.31x |
Financials
- P/E Ratio
- 13.45
- EPS (₹)
- 10.33
- RoCE
- 48.20%
- RoNW
- 99.59%
- PAT Margin
- 25.64%
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| NET Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves and Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowing | 38.17 | 15.01 | 10.49 | 9.61 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Bio Medica Laboratories This IPO | ₹52 Cr | 13.45 | 99.59% | 25.64% | 2.31x | -20.00% |
| Pramodini Medicare SME · listed 19 Aug 2026 | ₹69.04 Cr | 14.97 | 32.69% | 27.90% | 3.66x | +1.69% |
| ABH Healthcare SME · listed 1 Sep 2026 | ₹34.98 Cr | 20.69 | 39.07% | 10.74% | 1.42x | -2.94% |
| Avience Biomedicals SME · listed 25 Jun 2026 | ₹30.24 Cr | 16.56 | 49.89% | 15.86% | 385.4x | +90.00% |
| Speciality Medicines SME · listed 30 Mar 2026 | ₹29 Cr | 10.49 | 28.30% | 14.77% | 2.19x | 0.00% |
| Credent Connect N Care SME · listed 20 Aug 2026 | ₹93.9 Cr | 18.68 | 14.13% | 2.88% | 142.38x | +90.00% |
| Himalaya Nutravedics India SME · listed 29 Sep 2026 | ₹26.5 Cr | 12.63 | 45.12% | 17.16% | 2.24x | +11.32% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Bio Medica Laboratories plans to use the money raised, as stated in the offer document.
- Repayment of loan₹6.5 Cr
- Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises₹28.5 Cr
- General Corporate Purposes₹7.05 Cr
- Issue Expense₹5.14 Cr
About Bio Medica Laboratories
Bio Medica Laboratories is an Indian pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare and medicinal products. The company has built its presence in the pharmaceutical sector through quality-focused manufacturing practices and a diversified product portfolio catering to hospitals, clinics, and retail healthcare markets. Over the years, it has expanded its operations by focusing on customer relationships, product reliability, and compliance with industry standards. The company operates on a business model centred around the development, production, and distribution of pharmaceutical formulations and healthcare solutions across multiple therapeutic segments. Its product offerings include tablets, capsules, syrups, injections, and other medical formulations supplied through distributors and healthcare networks. The business is promoted by experienced industry professionals who focus on expanding market reach, improving manufacturing capabilities, and strengthening the company’s position in the domestic pharmaceutical industry.
Strengths
- Experienced promoters and management team with pharma industry knowledge.
- Diversified portfolio of injectable pharmaceutical products for human and veterinary use.
- Strong quality assurance systems supported by GMP-certified manufacturing facilities.
- Established relationships with clients across multiple Indian states and healthcare markets.
- Significant improvement in revenue, EBITDA margins, and profitability during recent financial years.
Risks
- High dependence on key customers may impact revenue if orders decline.
- Any quality control failure could damage reputation and invite legal liabilities.
- Failure to adopt new pharmaceutical technologies may affect future competitiveness.
- Negative cash flow risks may create pressure on expansion and working capital needs.
- The company operates from premises that are not fully owned, creating operational dependency risks.
Promoters and shareholding
Mukesh Mehta and Pradeep Mehta
- Promoter holding, pre-issue
- 99.99
- Promoter holding, post-issue
- 67.7%
Registrar, lead managers and documents
Lead manager
Company contact
Plot No.11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate, Indore, Madhya Pradesh, 452015
+91 7314102751
companysecretary@biomedica.co.inBio Medica Laboratories IPO: common questions
1.When does the Bio Medica Laboratories IPO open and close?
The Bio Medica Laboratories IPO opens on 21 May 2026 and closes on 25 May 2026.
2.What is the price band of the Bio Medica Laboratories IPO?
The price band is ₹132 – ₹139 per share, with a lot size of 1,000 shares and a minimum investment of ₹1,39,000.
3.What is the size of the Bio Medica Laboratories IPO?
The issue size is ₹52 Cr (Fresh capital cum OFS).
4.What is the GMP of the Bio Medica Laboratories IPO?
The last reported grey market premium is ₹2 per share as of 27 May 2026, 12:02 PM IST. GMP is unofficial and changes frequently.
5.When is the Bio Medica Laboratories IPO allotment?
The basis of allotment is expected on 26 May 2026. Allotment status can be checked with the registrar, Skyline Financial Services Private Limited.
6.When will the Bio Medica Laboratories IPO list?
The shares listed on 29 May 2026 on NSE SME.
7.Who is the lead manager of the Bio Medica Laboratories IPO?
The book running lead manager is Narnolia Financial Services Ltd, and the registrar is Skyline Financial Services Private Limited.
8.What will the money raised in the Bio Medica Laboratories IPO be used for?
As stated in the offer document, the proceeds are for: Repayment of loan; Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises; General Corporate Purposes; Issue Expense.
9.How can my company launch an IPO like Bio Medica Laboratories?
Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393